Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CTA’s Standards For Digital Therapeutics Clears Up ‘Industry Confusion’

Executive Summary

The Consumer Technology Association hopes its newly developed standard for digital therapeutics will clear up industry confusion and encourage the adoption of these treatments.

You may also be interested in...



Digital Health Roundup: Digital Therapeutics Push Ahead On Standards, Coverage; FDA’s Software Guidance

In this roundup feature focusing on developments in digital health, we highlight the key news and announcements from October.

PDT Company Better Therapeutics Ready To Go Public With SPAC Deal

Better Therapeutics is developing prescription digital therapeutics for behavioral therapy to address the root causes of cardiometabolic disease.

Pear Therapeutics Obtains First Medicaid Coverage For PDTs

Massachusetts’ Medicaid program will cover reSET and reSET-O prescription digital therapeutics for the treatment of substance abuse disorder and opioid use disorder.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT144614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel